Clinical Trials Logo

Clinical Trial Summary

The ReDy™ System (Renal Dynamics) is a renal denervation device incorporating a variety of ablation features and technical improvements over previously designed systems into a single product. It is intended to treat uncontrolled (drug-resistant) hypertension by RF ablation of the sympathetic nerve network surrounding the renal arteries.

This study will be carried out to validate the safety and the efficacy of the ReDy™ Renal Denervation device and to demonstrate that it performs according to its intended use, i.e. the treatment of patients with uncontrolled hypertension.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02690909
Study type Interventional
Source Renal Dynamics GmbH
Contact Erifyli Kalloudi
Phone +41(0)218048000
Email e.kalloudi@biosensors.com
Status Recruiting
Phase N/A
Start date April 2016
Completion date August 2017

See also
  Status Clinical Trial Phase
Completed NCT02832973 - Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension Phase 4
Terminated NCT02539810 - Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA) Phase 4
Recruiting NCT02210923 - Effect Baroreflex Activation Therapy on the Carotid Body N/A
Completed NCT02282033 - Safety and Performance Study of the Moderato System N/A
Completed NCT01173029 - Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events N/A
Active, not recruiting NCT02837445 - Moderato System: A Double-Blind Randomized Trial Ver 1.1 N/A
Terminated NCT02653222 - Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension Phase 2